Evidence map›Paper›PMID 21906628›Full record

ArticleAntiviral research2011

Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.

Morgan Hakki, Coyne Drummond, Benjamin Houser, Gail Marousek, Sunwen Chou

Abstract read
In one paragraph

Article in Antiviral research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Morgan HakkiDivision of Infectious Diseases, Oregon Health & Science University, Portland, OR 97239, USA. hakki@ohsu.edu
Coyne Drummond
Benjamin Houser
Gail Marousek
Sunwen Chou

Funding

ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUSR01AI039938 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI CHOU, SUNWEN · 1996 to 2013
$3.4M
NIAID NIH HHS R01 AI039938NIAID NIH HHS R01-AI39938
6 · The paper itself

Abstract

Select mutations in the human cytomegalovirus (HCMV) gene UL27 confer low-grade resistance to the HCMV UL97 kinase inhibitor maribavir (MBV). It has been reported that the 608-amino acid UL27 gene product (pUL27) normally localizes to cell nuclei and nucleoli, whereas its truncation at codon 415, as found in a MBV-resistant mutant, results in cytoplasmic localization. We now show that in the context of full-length pUL27, diverse single amino acid substitutions associated with MBV resistance result in loss of its nucleolar localization when visualized after transient transfection, whereas substitutions representing normal interstrain polymorphism had no such effect. The same differences in localization were observed during a complete infection cycle with recombinant HCMV strains over-expressing full-length fluorescent pUL27 variants. Nested UL27 C-terminal truncation expression plasmids showed that amino acids 596-599 were required for the nucleolar localization of pUL27. These results indicate that the loss of a nucleolar function of pUL27 may contribute to MBV resistance, and that the nucleolar localization of pUL27 during HCMV infection depends not only on a carboxy-terminal domain but also on a property of pUL27 that is affected by MBV-resistant mutations, such as an interaction with component(s) of the nucleolus.

Indexed as

Drug Resistance, ViralAntiviral AgentsBenzimidazolesCell NucleusCytomegalovirusCytomegalovirus InfectionsCytoplasmDichlororibofuranosylbenzimidazoleHumansMutation, MissenseRibonucleosidesViral ProteinsVirus ReplicationAntiviral AgentsBenzimidazolesDichlororibofuranosylbenzimidazolemaribavirRibonucleosidesViral Proteins

Identifiers

PMID21906628
PMCPMC3232008

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.